RxDoctor Payments Data

Jason Kim, DPM

Foot & Ankle Surgery · New York, NYNPI 1497103220

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (40.4%), education and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2020 at $5,361 and has fallen 82.9% since, to $916 in 2025. Among foot & ankle surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,107in general payments, 2019–2025

Across 144 payments — averaging $139.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gotham Surgical Solutions & Devices, Inc.$5K
  • Arthrex$3K
  • Integra Lifesciences Corporation$3K
  • Zimmer Biomet$2K
  • Suvon Surgical LLC$1K
  • Kerecis Limited$920
  • plus $5K from 21 others

What the payments were for

  • Travel & lodging$4,64923%
  • Food & beverage$8,11340%
  • Education$7,34537%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,107 in reported general payments places this provider in the 90th percentile of 652 foot & ankle surgery providers in New York.

See all foot & ankle surgery providers in New York

Medicare billing

Part B allowed, 2024
$101,031
Medicare patients
488
Services billed
846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.23$14,599
Ciclopirox49$1,480
Ketoconazole21$454
Ammonium Lactate20$445
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav29$303
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$252
Clotrimazole18$222
Terbinafine Hcl13$141
Doxycycline Hyclate14$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$881$14,59923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 foot & ankle surgery providers in New York.

Other foot & ankle surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →